Cartherics’ appointment of Laurence Nore underscores a growing trend with global implications. 

As global demand for biotechnology products and services continues to grow, innovation in the industry is becoming increasingly globalised. Cartherics Pty Ltd, a Melbourne-based biotech company pioneering cell-based immunotherapies, recently announced the appointment of U.S. life sciences executive Laurence Nore to its board of directors. This appointment reflects the importance of Australian biotech companies  gaining global insights and strategies for the commercialisation of technology so they can position themselves to compete and collaborate on a global scale.  

The Globalisation of Biotech Leadership 

The Australian biotech market is renowned for its world class research institutions and clinical trial infrastructure but is challenged by its size and amount of capital available to support late-stage development and commercialisation at scale. To address this more Australian biotech companies are collaborating with global talent, investors, and markets, particularly in the United States.  

This is where U.S.-based board members, like Laurence can make a significant impact. With more than two decades of experience in the American biotech landscape -including leadership positions at IgGenix and Medicines360, Nore brings a unique blend of commercial insight and operational experience. Her deep knowledge of product development, regulatory pathways, and market access in the U.S. will be a crucial asset as Cartherics continues to advance its cell therapy platforms. 

Australia: A Growing Biotech Hub 

Nore’s appointment also signals growing international recognition of Australia’s unique strengths in biotech innovation. “Australia is uniquely positioned to balance innovation with pragmatism,” she says, pointing to several national advantages: 

• Cutting-edge research infrastructure: Access to internationally recognised clinical trial centres enables rapid proof-of-concept. 

• Favourable R&D incentives: Government support through tax rebates reduces financial risk in early-stage development. 

• A stable geopolitical environment: While Australia’s biotech industry can be subject to supply chain issues and changing tariffs, Australia provides a stable, ethical environment for innovation. 

Collectively, these advantages make Australia an increasingly attractive destination for both talent and capital, particularly for cell-based immunotherapies.  

Cartherics: A Mission That Resonates 

For Nore, joining Cartherics is both a professional and deeply personal decision. The company’s work in CAR-NK cell therapies for cancer and endometriosis, aligns closely with her own career in oncology innovation. Having lost a close friend to aggressive renal cancer, Nore understands the urgency of developing more effective, tolerable treatments. 

“Cartherics represents hope,” she shares. “I want to be part of this journey.” 

Cartherics’ Focus on Women’s Health 

Looking beyond oncology, as a board member of Endodiag in France and former executive at women’s health-focused Medicines360, Nore brings a unique perspective to Cartherics’ efforts in endometriosis. Endometriosis is an area with significant unmet clinical need. It occurs in 1 in 7 females and those assigned female at birth, or 14% of girls and women in Australia are now estimated to live with endometriosis, up from 1 in 9 and 11% Her leadership reinforces Cartherics’ commitment to advancing solutions for diseases too often overlooked by mainstream investment. 

“Women can spend years navigating the healthcare system before receiving a diagnosis for endometriosis—one that is often invasive,” Nore notes. “Current treatments don’t target the root cause. That has to change.” 

Strategic Advantage: What U.S.-Based Directors Bring 

The benefits of including U.S.-based board members go beyond domain expertise. They offer: 

• Access to the world’s largest healthcare market, with insights into payer systems, reimbursement pathways, and commercial strategy. 

• Global investor connections that can support fundraising and partnerships beyond Australia’s borders. 

• Regulatory insight, helping to de-risk development strategies in jurisdictions like the U.S. FDA and European EMA. 

For Cartherics, Nore’s U.S. presence and European connections, bolstered by her French heritage and banking background, offer a rare trifecta of international perspective. 

Looking Forward 

Cartherics’ appointment of Laurence Nore exemplifies a broader trend: Australian biotech companies no longer operate in isolation. With promising therapies, local innovation, and international leadership, they are poised to play a larger role in shaping the future of global health. 

As Cartherics’ therapies move closer to clinical testing, the company is rewriting what’s possible when Australian innovation meets global ambition and forging new frontiers in cell therapies and innovation.